NSCLC Archives - DelveInsight

NSCLC

oncological-drugs-to-be-launch-in-2022
Most Promising Oncological Drugs Expected to Launch in 2022

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals...


pharma-news-for-noxxon-nuvalent-stryker-exact-sciences
Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trai...

Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move co...


drugs-launched-in-second-half-2021
Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate o...


pharma-news-for-edwards-lineage-novartis-koios-medical
Edwards’ Sapien 3 with Alterra Prestent; Koios Medical’s breast, thyroid cancer-spotting AI; Line...

Edwards secures FDA approval for Sapien 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Edwards Lifesciences declared to receive approval from the U.S. Food and Drug Admini...


tigit-Inhibitor-landscape
T-cell Immunoglobulin and ITIM domain (TIGIT) Inhibitor: An Insight into the Pipeline Development...

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a relatively new immunological checkpoint that has been studied as a potential immunotherapeutic target. TIGIT is a transmembrane glycopro...


Fda-Approved-Top-Drugs-Launched-in-2021
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of...

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceut...


biomarkers-in-non-small-cell-lung-cancer-treatment
Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer

The treatment options for  Non-Small Cell Lung Cancer (NSCLC) have been flooded in recent years due to improved methods of molecular profiling and better diagnostic tools. The new molecular b...


pharma-news-updates-for-amgen-verrica-nexturn-rosvivo-fennec
Amgen a leader in Undruggable Lung Cancer; Verrica’s Skin Disease Drug Delays; Fennec̵...

FDA Validates Use of Amgen’s KRAS Inhibitor in Lung Cancer  In a pathbreaking move, Amgen has gone ahead to emerge as a trailblazer in the undruggable lung cancer space with the approval o...


Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC
Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche’s Tecentriq R...

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innov...


Clover gets fund; Libtayo for first-line Advanced NSCLC Subset
Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for...

Clover Biopharmaceuticals Raises $230 Million  Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the ...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.